BioHarvest Sciences appoints two top-ranked law firms to pursue regulatory approvals of its cannabis and hemp products in US and Canada

BioHarvest Sciences appoints two top-ranked law firms to pursue regulatory approvals of its cannabis and hemp products in US and Canada

BioHarvest Sciences Inc. said it has appointed top-ranked law firms DLA Piper and GOWLING WLG to assist it in fulfilling all required compliance mandates and regulatory approvals to produce and commercialize cannabis and hemp products in the US and Canada. The Vancouver-based company said retaining legal counsel with experience and expertise in the US and Canadian cannabis and hemp industries has become a priority as the company advances its BioFarming technology to create cannabis and hemp products The technology is the first and only industrial-scale plant cell technology capable of producing active plant ingredients without the necessity to grow the plant itself. The company expects to commercialize its first cannabis-based products in the first half of 2022. READ: BioHarvest Sciences reports record 2Q sales orders in Israel After an extensive selection process, BioHarvest said both DLA Piper and GOWLING WLG had demonstrated the broad knowledge, creative thinking, and legal acumen to provide BioHarvest with the necessary guidance and strategic support to ensure regulatory compliance in these two key markets. The company said Dr Rhona Applebaum, a widely recognized and experienced leader at the nexus of industry, government, and civil society, led the selection process. She joined BioHarvest in November 2020 as a senior consultant, is now expanding her role to head all the cannabis regulatory affairs in North America. Lewis Retik, a partner at GOWLING WLG, noted that BioHarvest has emerged as a major disruptor in the global nutraceutical and cannabis sectors.  “GOWLING WLG is excited by the opportunity to help BioHarvest build upon this legacy, including its mission of introducing its sophisticated plant cell technology to Canada’s Cannabis industry,” he said.  BioHarvest CEO Ilan Sobel said the recently reached critical milestones in its cannabis and cannabinoid development program that underscore the urgency of obtaining all the necessary legal and regulatory approvals.  “Cannabis and cannabinoids represent an important vertical for BioHarvest. With our technology, we believe we can help meet the demand for high quality, consistent and sustainable medicinal and wellbeing products,” he said in a statement.  “The US and Canadian Cannabis markets represent major opportunities for the Company. Consequently, we are focusing our efforts on these two critical markets. We are certain we can benefit from the guidance and support of DLA Piper and Gowling WLG, two exceptional law firms with proven track records in navigating this sector,” Sobel added. Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham